Alliance was founded in 1996 by John Dawson and commenced trading in 1998, when the company entered into a fostering arrangement with Novartis, under which Alliance took over the marketing and distribution of 16 of Novartis’ speciality prescription brands. Since then the company has grown to owning or licensing the rights to over 60 products.
Prior to setting up Alliance, John had built up multidisciplinary experience in the pharmaceutical industry over a period of some 30 years and had held a number of senior roles at Sandoz (now Novartis AG). John continues to actively lead the Alliance business today, as its CEO.
The business has grown consistently over the years, through a combination of targeted acquisitions and organic growth, floating on the Alternative Investment Market (AIM) of the London Stock Exchange in 2003.
Recent years have seen a broadening in the scope of Alliance’s product portfolio. In addition to the established niche prescription products which formed the original focus of the company’s activities (and which still constitute the bulk of our business), Alliance’s portfolio now includes a number of medical devices and consumer products, covering a wide range of therapy areas.
Having completed a total of 28 acquisitions to date, together with a number of in-licensing deals, Alliance now owns or licenses the rights to over 60 pharmaceutical and related products. In addition to its UK operations, the company is growing its International footprint and now has a direct presence in France, Germany, the Republic of Ireland and China, with a group turnover of nearly £100 million.
In recent years the business has expanded its UK head office in Chippenham, Wiltshire, and is one of the main employers in the area.